Search results for " Myeloproliferative"

showing 7 items of 17 documents

Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.

2016

IF 10.383; International audience; OBJECTIVES: Cancer may be a complication of inflammatory bowel disease (IBD) or its treatment. In elderly onset IBD patients the risk of malignancy is of particular concern. We studied this risk in a population-based cohort of elderly onset IBD patients.METHODS: In a French population-based cohort, we identified 844 patients aged >60 years at IBD diagnosis from 1988 to 2006, including 370 Crohn's disease (CD) and 474 ulcerative colitis (UC). We compared incidence of cancer among IBD patients with that observed in the French Network of population-based Cancer Registries (FRANCIM). Confidence interval (CI) was estimated assuming a Poisson-specific law for ra…

MESH: CarcinomaMaleNonmelanoma Skin-CancerInflammatory bowel disease0302 clinical medicineAdrenal Cortex HormonesAzathioprineMESH: IncidenceAge of OnsetAged 80 and overeducation.field_of_studyMESH: Middle AgedRheumatoid-ArthritisIncidenceGastroenterologyMESH: Follow-Up StudiesMESH: Anti-Inflammatory Agents Non-Steroidal3. Good health030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Immunosuppressive Agentsmedicine.medical_specialtyMESH: Age of OnsetMESH: Colitis Ulcerativedigestive systemMESH: Adrenal Cortex Hormones03 medical and health sciencesIntestinal NeoplasmsHumansCrohns-DiseaseeducationMESH: Intestinal NeoplasmsMESH: Protective FactorsMESH: AzathioprineAgedRetrospective StudiesMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphaMESH: Retrospective Studiesmedicine.diseaseMESH: Inflammatory Bowel DiseasesInflammatory Bowel Diseasesdigestive system diseasesLymphoproliferative DisordersMethotrexateMESH: Tumor Necrosis Factor-alphaColitis UlcerativeComplicationMESH: FemaleProspective Observational CohortTime FactorsMESH: RegistriesMESH: Proportional Hazards ModelsMaintenance TherapyMESH: Aged 80 and overMESH: Lymphoproliferative DisordersCrohn DiseaseMESH: Risk FactorsRisk FactorsNeoplasmsMESH: NeoplasmsRegistriesUlcerative-ColitisMesalamineMESH: AgedIncidence (epidemiology)Anti-Inflammatory Agents Non-SteroidalMetaanalysisMiddle AgedhumanitiesMESH: MethotrexateFemaleFranceFrench PopulationColorectal NeoplasmsImmunosuppressive AgentsMESH: Myeloproliferative DisordersPopulationColorectal-CancerIncreased RiskInternal medicinemedicineProportional Hazards ModelsMyeloproliferative DisordersHepatologybusiness.industryMESH: Time FactorsCarcinomaCancerRetrospective cohort study[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: MesalamineProtective FactorsMESH: MaleMESH: FranceAge of onsetbusinessMESH: Colorectal NeoplasmsFollow-Up StudiesThe American journal of gastroenterology
researchProduct

Comparison between thrombotic risk scores in essential thrombocythemia and survival implications.

2019

The conventional thrombotic risk stratification in essential thrombocythemia (ET) distinguishes patients in two risk groups based on previous thrombosis and age (< or >60). The IPSET-thrombosis takes into account four risk factors: age greater than 60 years and the presence of CV risk factors, thrombosis history and JAK2 V617F presence. The revised IPSET-thrombosis uses three adverse variables to delineate four risk categories: age greater than 60, thrombosis history, and JAK2 V617F presence. We compared different risk models in the estimation of thrombotic risk in 191 patients with ET and the role of specific driver mutations affecting overall survival, according to thrombotic risk. …

MaleCancer ResearchEssential Thrombocythemia Myeloproliferative Thrombosis Thrombotic risk SurvivalKaplan-Meier EstimateSeverity of Illness IndexSettore MED/15 - Malattie Del SanguePrognostic score0302 clinical medicineRisk groupsRecurrenceRisk FactorsMutational statusThrombophiliaAged 80 and overIncidenceAge FactorsHematologyGeneral MedicineMiddle AgedPrognosisThrombosisOncology030220 oncology & carcinogenesisFemaleJAK2 V617FReceptors ThrombopoietinThrombocythemia EssentialAdultPoor prognosismedicine.medical_specialtyAdolescentMutation MissenseModels BiologicalRisk Assessment03 medical and health sciencesYoung AdultInternal medicinemedicineHumansAgedRetrospective StudiesThrombotic riskbusiness.industryEssential thrombocythemiaThrombosisJanus Kinase 2medicine.diseasebusinessCalreticulin030215 immunologyFollow-Up StudiesHematological oncologyREFERENCES
researchProduct

Immunohistochemical evaluation of bone marrow lymphoid nodules in chronic myeloproliferative disorders

1991

One hundred and seventy bone marrow biopsies from patients with chronic myeloproliferative disorders (CMPDs) were evaluated for the presence of lymphoid nodules (LNs) and were immunostained using a panel of monoclonal antibodies (UCHL1, 4KB5 and L26) recognizing different lymphocyte antigens. LNs were found in 35% of cases of idiopathic thrombocythaemia, 24.6% of myelofibrosis/osteomyelosclerosis, 18.2% of polycythaemia vera 12.1% of chronic myeloid leukaemia and 19.2% of borderline cases. Varying degrees of immunohistochemical positivity for the three antibodies tested were found. LNs were always made up of variable proportions of both T- and B-lymphocytes with a prevalence of T-cells. Thi…

MalePolycythaemiaPathologymedicine.medical_specialtymedicine.drug_classMonoclonal antibodyPathology and Forensic MedicineBone Marrowhemic and lymphatic diseasesmedicineHumansLymphocytesMyelofibrosisMolecular BiologyAgedMyeloproliferative Disordersintegumentary systembiologybusiness.industryAntibodies MonoclonalCell BiologyGeneral MedicineMiddle Agedmedicine.diseaseImmunohistochemistryChronic myeloproliferative disordersmedicine.anatomical_structureChronic DiseaseMonoclonalbiology.proteinImmunohistochemistryFemaleBone marrowAntibodybusinessVirchows Archiv A Pathological Anatomy and Histopathology
researchProduct

Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis

2020

BACKGROUND AND OBJECTIVE MYELOFIBROSIS: is an infrequent chronic myeloproliferative neoplasm. We aimed to describe the clinico-biological characteristics, treatment, and evolutive course of myelofibrosis patients in Spain.; MATERIAL AND METHODS: A total of 1,000 patients from the Spanish Registry of Myelofibrosis diagnosed with primary (n=641) or secondary (n=359) myelofibrosis were analysed.; RESULTS: Median age was 68 years. The frequency of constitutional symptoms, moderate to severe anaemia (Hb<10g/dL), and symptomatic splenomegaly was 35%, 36%, and 17%, respectively. The rate of thrombosis and haemorrhage was 1.96 and 1.6 events per 100 patient-years, respectively. The cumulative incid…

Moderate to severePediatricsmedicine.medical_specialtyConstitutional symptomsbusiness.industrymedicine.diseaseTransplantation03 medical and health sciences0302 clinical medicineChronic Myeloproliferative NeoplasmClinical heterogeneitymedicineElderly people030212 general & internal medicineMyelofibrosisbusinessPrognostic modelsMedicina Clínica (English Edition)
researchProduct

Clinical history of thrombosis before diagnosis of overt myeloproliferative neoplasms in triple negative patients

2017

Thromboses are the most important preventable risk factors for morbidity and mortality in myeloproliferative neoplasms (MPN). We here performed a retrospective cross sectional study of patients with a diagnosis of Philadelphia negative MPN and a prior history of thrombosis, analyzed from electronic charts. Among a cohort of 260 patients with MPNs (78PV, 102ET, 80 MF), forty four were found triple negative for JAK-2, calreticulin and MPL gene mutations. Sixty-nine (26.54%) patients (29F, 40M) had a personal past clinical history of arterial or venous thrombosis. Among patients with thrombosis, 13(18.8%) cases (11ET, 2MF) were triple negative (median age:60 years). Most events, in particular …

chronic Myeloproliferative neoplasmchronic Myeloproliferative neoplasms; ThrombosisThrombosis
researchProduct

Familial essential thrombocythemia: 6 cases from a mono‐institutional series

2022

Rarely essential thrombocythemia (ET) is diagnosed in more than one person within a family. Familial myeloproliferative neoplasms are underdiagnosed. In this report, we describe 6 couples of familial ET, evaluating the heterogeneity of the mutational state and the clinical presentation.

essential thrombocythemia familial myeloproliferative neoplasmsGeneral MedicineClinical Case Reports
researchProduct

Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregna…

2021

Abstract Myeloproliferative neoplasms (MPN) are traditionally regarded as a disease of older adults, though a not negligible fraction of cases occurs at a younger age, including women of childbearing potential. MPN in younger patients, indeed, offer several challenges for the clinical hematologist, that goes from difficulties in reaching a timely and accurate diagnosis to a peculiar thrombotic risk, with a relatively high incidence of thromboses in unusual sites (as the splanchnic veins or the cerebral ones). Moreover, the issue of pregnancy is recently gaining more attention as maternal age is rising and molecular screening are widely implemented, leading to a better recognition of these c…

medicine.medical_specialtyPhiladelphia Chromosome NegativeMyeloproliferative neoplasmDiseaseEssential thrombocythemiaCritical discussionMyeloproliferative neoplasmsAntiphospholipid syndromePregnancyNeoplasmsmedicineHumansPhiladelphia ChromosomeHematologistIntensive care medicineAgedEssential thrombocythemia; Myeloproliferative neoplasms; PregnancyPregnancyMyeloproliferative DisordersEssential thrombocythemiabusiness.industryIncidencefood and beveragesThrombosisHematologymedicine.diseaseOncologyYounger adultsFemalebusinessmanagement
researchProduct